Company profile

ActoGeniX was founded in June 2006 as a spin-off of the Flemish Institute for Biotechnology (VIB) and the University of Ghent. ActoGeniX develops therapies, based on its patented TopAct™ technology platform, which address major diseases requiring intensive medical care, including gastrointestinal problems, auto-immunity diseases, allergies and metabolic disorders. TopAct™ uses micro-organisms for the oral administration of proteins. ActoGeniX’s first product – for treating Crohn’s disease - has already been successfully tested on patients.

ActoGeniX
  • Activity: Oral delivery of biopharmaceuticals
  • Website: www.actogenix.com
  • Location: Belgium
  • Entry: 2006
  • Platform: Health & Care